Last updated: July 27, 2026
AbbVie v. Mylan (case no. 1:13-cv-01072) is a U.S. patent infringement dispute tied to Mylan’s proposed generic entry associated with AbbVie’s product portfolio. The record-driven enforcement posture in this matter centers on patent validity and infringement for the asserted Orange Book-listed patents, with the litigation procedural history tracking the standard Paragraph IV framework: complaint filing, contested claim construction and validity contentions, and resolution through a merits outcome and/or settlement that controlled timing of generic launch.
H1: AbbVie v. Mylan 1:13-cv-01072 Litigation Summary, Patent Claims, and Generic Launch Impact
What is AbbVie Inc. v. Mylan Pharmaceuticals Inc., 1:13-cv-01072 about?
The case caption identifies AbbVie Inc. as plaintiff and Mylan Pharmaceuticals Inc. as defendant under U.S. federal docket 1:13-cv-01072. In Paragraph IV litigation, the complaint typically asserts one or more Orange Book patents listed for the brand drug at issue, alleging that the proposed generic would infringe (directly, indirectly, or under the doctrine of equivalents) and that the asserted patents are invalid or otherwise unenforceable only at the defendant’s behest.
Core litigation questions in Paragraph IV disputes
- Does the proposed generic product infringe the asserted claims?
- Are the asserted patents invalid for obviousness, anticipation, lack of written description/enablement, indefiniteness, or other statutory grounds?
- Are the asserted patents enforceable against the specific marketing activities described in the litigation record?
- What remedies apply, including injunctive relief and damages for infringement during the statutory period (if any)?
Which Orange Book patents and claims were typically at issue in this docket?
Paragraph IV suits in this context usually assert:
- composition or active ingredient claims,
- formulation or dosage-form claims (including release profiles if applicable),
- method-of-use claims tied to indications,
- and sometimes manufacturing-related claims.
Actionable impact of claim scope
- Broad composition claims can drive earlier resolution because generic infringement theories hinge on equivalence of API and essential excipients.
- Method-of-use claims add evidentiary complexity tied to proposed labeling and promotional materials.
Which patents were asserted in AbbVie v. Mylan 1:13-cv-01072?
No complete list of asserted patent numbers, claim(s), and specific Orange Book listings is provided in the prompt. Without the asserted-patent identifiers and claim mapping from the complaint and orders, a precise patent-by-patent breakdown would be incomplete.
What procedural milestones occurred in 1:13-cv-01072?
A complete, accurate procedural timeline requires docket entries (complaint date, answer, Rule 12 motions, claim construction schedule, Markman hearing, summary judgment or dispositive motion dates, and final judgment/settlement).
The prompt provides only the case number and parties, which is insufficient to reconstruct a litigation-grade chronology.
How did claim construction and validity arguments affect outcomes?
Patent litigation outcomes in Paragraph IV matters typically turn on:
- claim construction defining essential claim terms,
- whether the prior art teaches or renders the claimed subject matter obvious,
- whether the asserted claims are enabled and described adequately in the specification,
- and whether the proposed generic can be designed around without changing the core product.
Without the court’s claim construction rulings or summary judgment record for this docket, the legal impact cannot be stated reliably.
Was there a Paragraph IV (Hatch-Waxman) settlement or merits judgment?
Paragraph IV cases frequently end via:
- merits judgment (infringement and validity determinations),
- dismissal or noninfringement findings,
- or a settlement with a “launch-at” effective date and/or covenant not to sue.
A determination for 1:13-cv-01072 requires settlement documents or final judgment docket entries, which are not included in the prompt.
When did Mylan’s generic launch risk materialize based on 1:13-cv-01072?
Launch risk is driven by:
- the 30-month stay triggered by the Paragraph IV notice,
- whether the case reached a final decision before stay expiration,
- and any settlement that carves out a later effective launch date.
A launch timeline cannot be quantified without:
- the Paragraph IV notice date,
- the complaint filing date (for stay timing),
- the earliest trial date or dispositive motion decision date,
- and the final resolution date.
What does this litigation mean for AbbVie’s patent estate strength?
Litigation can signal:
- whether key patents survive invalidity attacks,
- how defensible claim scope is under claim construction,
- and whether the brand’s enforcement strategy achieved earlier market exclusion.
A strength analysis requires the court’s holdings on infringement and validity. No holding data is provided.
How strong is Mylan’s risk posture in this docket?
Defendant risk is typically assessed by:
- likelihood of an adverse claim construction,
- exposure to injunction/damages,
- and the ability to design around asserted claims while keeping an equivalent product.
No specifics on claim scope or asserted patents are available in the prompt.
Does the case involve formulation, method-of-use, or manufacturing patents?
Without the patent numbers and their claim categories, the docket cannot be classified by technology type (composition/formulation/method-of-use/manufacturing).
Which jurisdictions and courts control enforceability in 1:13-cv-01072?
The docket is U.S. federal, but the prompt does not provide:
- the district and judge,
- the relevant court orders that define the controlling precedent,
- or any appellate history.
What is the settlement and licensing profile for AbbVie vs. Mylan here?
Settlement terms in Hatch-Waxman disputes often include:
- an agreed “at-risk” or delayed launch date,
- payment or consideration for delay (where permitted),
- cross-licensing or covenants not to sue for additional patents,
- and stipulated dismissal terms.
The prompt provides no settlement terms.
How does this compare with other AbbVie generic disputes against Mylan?
A meaningful comparison needs:
- a list of other AbbVie-vs-Mylan litigations,
- their asserted patents,
- and their outcomes.
Those data are not included.
Key Takeaways
- AbbVie v. Mylan, docket 1:13-cv-01072, is a Hatch-Waxman-style patent infringement action tied to an Orange Book patent enforcement posture.
- The prompt lacks asserted patent numbers, claim categories, court rulings, and final resolution data required for litigation-grade analysis (patent-by-patent, timeline, validity/infringement holdings, settlement terms, and launch impact).
- No quantifiable conclusions on exclusivity timing, generic launch dates, or patent estate strength can be supported from the provided information.
FAQs
- What is the legal significance of a Paragraph IV filing in AbbVie v. Mylan-type cases?
- How does claim construction typically drive infringement outcomes in Orange Book patent disputes?
- What are the most common invalidity theories (obviousness, anticipation, indefiniteness) used in Hatch-Waxman litigation?
- How do 30-month stays interact with final court decisions in determining launch timing?
- What settlement structures are most common in brand vs. generic Paragraph IV cases?
References
- Federal court case docket referenced by user: AbbVie Inc. v. Mylan Pharmaceuticals Inc., 1:13-cv-01072.
